Alzheimer's market will double in value between 2013 and 2023

7 May 2015

The global Alzheimer’s market will more than double between 2013 and 2023, according to research and consulting firm GlobalData.

This market sector is projected to go from a value of $4.9 billion in 2013 to an estimated value of $13.3 billion by 2023, a compound annual growth rate of 10.5%. This will be driven by the launch of 15 new therapies, including several drug candidates with the potential to modify the underlying cause of Alzheimer’s.

Increasing prevalence in the nine major markets, along with advances in diagnostic capability and increased social awareness, will also contribute to market growth.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK